Home › Retinoblastoma › NCT03932786
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)
Who can join
All ages · All sexes · Healthy volunteers welcome
Full eligibility criteria
* Unilateral or bilateral intraocular retinoblastoma * Diagnosis between the ages of 0 - 17.99 years * Diagnosis on or after January 1, 2008 * No exclusions based on primary or secondary treatment modalities * Retrospective group patients must be ≥ 6 months post end of treatment at study entry * For those already at this timepoint, they are now eligible * For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment * Prospective group patients must not have begun treatment * Patients with diminished capacity will not be enrolled. * Language: Patients must be able to communicate in English, French, or Spanish * Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient. * Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.
About the study
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
What is being tested
- Biospecimen collection (procedure)
- Vision assessment (other)
- Questionnaire administration (other)
- Quality of life assessment (other)
- Laboratory Biomarker Analysis (other)
Sponsor: Vanderbilt-Ingram Cancer Center · Participants: 900 · Started: Jan 24, 2019
Contact the study team
- Vanderbilt-Ingram Service for Timely Access · Phone: 800-811-8480
Official record on ClinicalTrials.gov — NCT03932786
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.